Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Lys-Glu-Asp-Ala
Also known as: KEDA
Formula C18H31N5O9
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala / KEDA) from the Khavinson short-peptide 'bioregulator' series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Marketed in Russia primarily as a food-supplement-grade cytomax; not FDA-approved in the US; research-use only.
Khavinson-group studies report that Livagen induces activation of ribosomal genes, decondensation of pericentromeric heterochromatin, and de-repression of genes silenced during aging in lymphocytes from elderly donors. Proposed activity is direct binding to DNA / chromatin. Western pharmacology literature has not independently characterized its mechanism.
Evidence base is essentially single-lab (Khavinson, Lezhava, and collaborators). In vitro studies on lymphocyte chromatin in elderly subjects and small Russian reports in chronic gastritis and immune senescence. No FDA-registered clinical trials and no Western RCTs.
Aggregated from 9 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
9
Verified labs
0
Avg purity
99.62%
±0.26%
Endotoxin tested
44%
Scored vendors carrying Livagen, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.
Compare Livagen prices & $/mg2 prescribers in our directory work with Livagen, each confirmed from their own website. Peptides like Livagen require a prescription from a licensed provider.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.